PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15138560-10	2004	The early increase in TPO (the percentage increase in TPO at day 4) was significantly greater (p=0.0345) in patients treated with paclitaxel/carboplatin combination (57.8+/-44.5%) compared with single-agent carboplatin (21.3+/-34.1%).	Carboplatin	141-152	thrombopoietin	Homo sapiens	22-25	
15138560-10	2004	The early increase in TPO (the percentage increase in TPO at day 4) was significantly greater (p=0.0345) in patients treated with paclitaxel/carboplatin combination (57.8+/-44.5%) compared with single-agent carboplatin (21.3+/-34.1%).	Carboplatin	141-152	thrombopoietin	Homo sapiens	54-57	
15138560-10	2004	The early increase in TPO (the percentage increase in TPO at day 4) was significantly greater (p=0.0345) in patients treated with paclitaxel/carboplatin combination (57.8+/-44.5%) compared with single-agent carboplatin (21.3+/-34.1%).	Carboplatin	207-218	thrombopoietin	Homo sapiens	22-25	
15138560-10	2004	The early increase in TPO (the percentage increase in TPO at day 4) was significantly greater (p=0.0345) in patients treated with paclitaxel/carboplatin combination (57.8+/-44.5%) compared with single-agent carboplatin (21.3+/-34.1%).	Carboplatin	207-218	thrombopoietin	Homo sapiens	54-57	
15138560-12	2004	The observed platelet-sparing effect of the paclitaxel/carboplatin might be related to the early increase in circulating TPO levels, although the precise mechanism remains to be elucidated.	Carboplatin	55-66	thrombopoietin	Homo sapiens	121-124	
11157479-5	2001	Compared to normal controls, serum Tpo levels in patients receiving paclitaxel and carboplatin were significantly elevated 5 hours after infusion and remained elevated at day 7 (287% +/- 63% increase, P <.001).	Carboplatin	83-94	thrombopoietin	Homo sapiens	35-38	
14584274-3	2003	This study investigated the time-course of the changes in the platelet count and the circulating concentration of thrombopoietin (TPO), a platelet growth factor, during combination chemotherapy consisting of carboplatin and docetaxel.	Carboplatin	208-219	thrombopoietin	Homo sapiens	114-128	
14584274-3	2003	This study investigated the time-course of the changes in the platelet count and the circulating concentration of thrombopoietin (TPO), a platelet growth factor, during combination chemotherapy consisting of carboplatin and docetaxel.	Carboplatin	208-219	thrombopoietin	Homo sapiens	130-133	
14584274-9	2003	These results suggest that docetaxel might also have a platelet-sparing effect on the anti-platelet activity of carboplatin, mediated by levels of circulating TPO concentration.	Carboplatin	112-123	thrombopoietin	Homo sapiens	159-162	
10691586-0	2000	Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.	Carboplatin	44-55	thrombopoietin	Homo sapiens	18-32	
10691586-7	2000	INTERVENTION: Recombinant human thrombopoietin was given before chemotherapy and after a second cycle of carboplatin therapy.	Carboplatin	105-116	thrombopoietin	Homo sapiens	32-46	
9848114-2	1998	Previous studies indicate that administration of pegylated recombinant human (PEG-rHu) MGDF in combination with recombinant murine granulocyte colony-stimulating factor (rMuG-CSF) prevented lethality and reduced hematotoxicity in carboplatin-treated/irradiated mice, a disease-state animal model of radio-chemotherapy.	Carboplatin	230-241	thrombopoietin	Homo sapiens	87-91	
10216474-0	1999	The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer.	Carboplatin	25-36	thrombopoietin	Homo sapiens	51-65	
10497847-1	1999	We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on carboplatin-induced thrombocytopenia in rats.	Carboplatin	116-127	thrombopoietin	Homo sapiens	55-98	
9010146-2	1997	METHODS: We conducted a randomized, double-blind, placebo-controlled dose-escalation study of MGDF in 53 patients with lung cancer who were treated with carboplatin and paclitaxel.	Carboplatin	153-164	thrombopoietin	Homo sapiens	94-98	
9722306-0	1998	The haemopoietic effects of thrombopoietin administered post-myelosuppressive carboplatin therapy compared to either pre- and post- or pre-chemotherapy.	Carboplatin	78-89	thrombopoietin	Homo sapiens	28-42	
9772477-1	1997	OBJECTIVES: To explore that COS-7 cells efficiently transfected with human thrombopoietin (hTPO) cDNA from fetal liver and hTPO potentially treated carboplatin-induced thrombocytopenia in mice.	Carboplatin	148-159	thrombopoietin	Homo sapiens	75-89	
31903256-0	2019	Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model.	Carboplatin	150-161	thrombopoietin	Homo sapiens	18-32